Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Quercetin  COVID-19 treatment studies for Quercetin  C19 studies: Quercetin  Quercetin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  

A role for quercetin in coronavirus disease 2019 (COVID-19)

Derosa et al., Phytotherapy Research, doi:10.1002/ptr.6887 (Review)
Derosa et al., A role for quercetin in coronavirus disease 2019 (COVID-19), Phytotherapy Research, doi:10.1002/ptr.6887 (Review)
Oct 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Review noting that quercetin has a theoretical, but significant, capability to interfere with SARS-CoV-2 replication, with results showing this to be the fifth best compound out of 18 candidates.
Derosa et al., 9 Oct 2020, peer-reviewed, 4 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperQuercetinAll
Abstract: Received: 24 May 2020 Revised: 5 September 2020 Accepted: 13 September 2020 DOI: 10.1002/ptr.6887 REVIEW A role for quercetin in coronavirus disease 2019 (COVID-19) Giuseppe Derosa1,2 | Pamela Maffioli1 | 1 Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy 2 Laboratory of Molecular Medicine, University of Pavia, Pavia, Italy 3 Velleja Research S.r.l., Milan, Italy Correspondence Giuseppe Derosa, Department of Internal Medicine and Therapeutics, University of Pavia, Via Aselli, 43/45, 27100 Pavia, Italy. Email: giuseppe.derosa@unipv.it Angela D'Angelo2 | Francesco Di Pierro3 Several months ago, an outbreak of pneumonia of unknown aetiology was detected in Wuhan City (China) and the aetiological agent of the atypical pneumonia was isolated by the Chinese authorities as novel coronavirus (2019-nCoV or SARS-CoV-2). The WHO announced this new disease was to be known as “COVID-19.” When looking for new antiviral compounds, knowledge of the main viral proteins is fundamental. The major druggable targets of SARS-CoV-2 include 3-chymotrypsin-like protease (3CLpro), papain-like protease (PLpro), RNA-dependent RNA polymerase, and spike (S) protein. Quercetin inhibits 3CLpro and PLpro with a docking binding energy corresponding to −6.25 and −4.62 kcal/mol, respectively. Quercetin has a theoretical, but significant, capability to interfere with SARS-CoV-2 replication, with the results showing this to be the fifth best compound out of 18 candidates. On the basis of the clinical COVID-19 manifestations, the multifaceted aspect of quercetin as both antiinflammatory and thrombin-inhibitory actions, should be taken into consideration. KEYWORDS COVID-19, infectious diseases, nutraceutical, quercetin, SARS-CoV-2 1 | I N T RO DU CT I O N appeared in Europe. The virus was isolated in Bavaria (Germany) from a German patient infected by an individual from Shanghai (China). Viral diseases continue to pose a serious threat to public health. The Subsequently, the virus was present in Italy on January 25, 2020. The world has witnessed several viral epidemics over the past 20 years, unsuspecting individuals infected with the virus are thought to have including severe acute respiratory syndrome (SARS) coronavirus been able to circulate in the area of Basso Lodigiano with few symp- (SARS-CoV-1) in 2003, the influenza disease called H1N1 in 2009, toms or with symptoms mistaken for those of influenza. and the middle east respiratory syndrome (MERS) coronavirus (MERS- On January 30, 2020, the WHO declared the situation a public CoV) in 2012. Several months ago, an outbreak of pneumonia of health unknown aetiology was detected in Wuhan City, Province of Hubei Organization, 2020a) and on February 11, 2020, the WHO announced emergency of international concern (World Health (China) and reported to the China Country Office of the World Health that the disease caused by this new virus was to be known as Organization (WHO) on December 31, 2019. The National Health “COVID-19,” which is an acronym of “coronavirus disease-2019.” Commission of China reported the outbreak was associated with On February 20, 2020, the first symptomatic COVID-19 patient exposure in one seafood market in Wuhan City. The aetiological agent was identified in Italy at the Emergency Department of Codogno Hos- of the atypical pneumonia was isolated on January 7, 2020 by the pital, Basso Lodigiano, Province of..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit